Clinical Trial Update: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating 17-DMAG (alvespimycin), an HSP90 inhibitor, in patients with metastatic or unresectable solid tumors or lymphomas. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Mycosis Fungoides Sezary Syndrome

Drugs mentioned

• 17-DMAG (alvespimycin) (alvespimycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Status: COMPLETED